Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Laurus Labs Limited Capital/Financing Update 2024

Feb 17, 2024

62639_rns_2024-02-17_7b6ceb03-c2fa-4e28-8aa6-c2bd9d7bbe54.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

February 17, 2024

==> picture [452 x 75] intentionally omitted <==

To
The Corporate Relations Department
BSE Limited
Phiroz Jeejeebhoy Towers, 25thFloor,
Dalal Street
Mumbai – 400001
Code: 540222
To
The Listing Department
National Stock Exchange of India Limited,
Exchange Plaza,
Bandra Kurla Complex, Bandra (East)
Mumbai – 400 051
Code: LAURUSLABS

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform that the Company has infused further equity into its wholly-owned subsidiary M/s. Laurus Synthesis Private Limited (LSPL) via subscribing to the rights issue offered by LSPL for a cash consideration of Rs. 99,13,12,308/- for acquisition of 7,600 Equity shares of Rs. 10 each at a premium of Rs. 1,30,425.83/- per share.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations read with Section V -A of Chapter V of Master Circular issued vide circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, is also attached as per ‘Annexure’.

This is for your information and record.

Yours faithfully,

For Laurus Labs Limited

VENKATESWAR Digitally signed by VENKATESWAR REDDY GOGIREDDY REDDY GOGIREDDY Date: 2024.02.17 12:05:56 +05'30' G. Venkateswar Reddy Company Secretary & Compliance Officer

==> picture [452 x 43] intentionally omitted <==

==> picture [452 x 75] intentionally omitted <==

Annexure

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) name of the target entity, details in brief such
as size, turnover etc.;
M/s. Laurus Synthesis Private Limited (LSPL)
(Wholly-Owned Subsidiary of M/s. Laurus Labs
Limited)
Turnover(FY 2022-23)– Rs.108 Crores
b) whether the acquisition would fall within
related party transaction(s) and whether the
promoter/ promoter group/ group companies
have any interest in the entity being acquired? If
yes, nature of interest and details thereof and
whether the sameis doneat “arm’slength”;
Yes. The transaction is a related party as LSPL is
a wholly-owned subsidiary of the Company.
None of the promoter/ promoter group/ group
companies have any interest in LSPL and the
transaction is done at arm’s length basis
c) industry to which the entity being acquired
belongs;
Pharmaceutical
d) objects and impact of acquisition (including
but not limited to, disclosure of reasons for
acquisition of target entity, if its business is
outside the main line of business of the listed
entity);
The Company has infused further equity via
rights issue keeping in view of the funds
requirements of LSPL
e) brief details of any governmental or
regulatoryapprovals required for the acquisition
No
f) indicative time period for completion of the
acquisition;
The Company has paid the share application
money and 7600 Equity shares of Rs. 10 each
were allotted.
g) consideration - whether cash consideration or
share swap or any other form and details of the
same;
Cash Consideration
h) cost of acquisition and/or the price at which
the shares are acquired;
Rs. 99,13,12,308/- for 7,600 equity of shares of
Rs. 10 each at a premium of Rs. 1,30,425.83/-
per share.
i) percentage of shareholding / control acquired
and/or number of shares acquired;
100%
j) brief background about the entity acquired in
terms of products/line of business acquired, date
of incorporation, history of last 3 years turnover,
country in which the acquired entity has
presence and any other significant information
(in brief);
M/s. Laurus Synthesis Private Limited, a
wholly-owned subsidiary of M/s. Laurus Labs
Limited,is a leading Contract Development &
Manufacturing Organization (CDMO) with a
solid track record in supporting drug
development and manufacturing programs of
global pharmaceutical and biotech companies.
Date of incorporation: May 18, 2020
Last 3 years turnover:
FY 2022-23: Rs. 108 Crores
FY 2021-22: Rs. 91.20 Crores
FY 2020-21: Rs. 15.63 Crores

VENKATESWA Digitally signed by VENKATESWAR REDDY R REDDY GOGIREDDY Date: 2024.02.17 GOGIREDDY 12:06:17 +05'30'

==> picture [452 x 43] intentionally omitted <==